Related Experiment Video

Updated: May 30, 2026

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy (PRRT): 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
09:49

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy (PRRT): 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

Patient doses in paediatric CT: feasibility of setting diagnostic reference levels

H Järvinen1, K Merimaa, R Seuri

  • 1Radiation and Nuclear Safety Authority, STUK, PO Box 14, FI-00881 Helsinki, Finland. hannu.jarvinen@stuk.fi

Radiation Protection Dosimetry
|July 26, 2011
PubMed

Insights

Setting pediatric diagnostic reference levels (DRLs) for computed tomography (CT) requires collecting patient dose data by age or weight. DRLs for pediatric chest CT should be a curve based on weight, while head CT DRLs can use age groups.

Area of Science:

  • Medical Imaging
  • Radiology
  • Radiation Protection

Background:

  • Doses to pediatric patients from computed tomography (CT) examinations are a significant concern.
  • Limited data and studies exist for establishing pediatric diagnostic reference levels (DRLs).
  • This highlights a critical gap in radiation safety protocols for children undergoing CT scans.

Purpose of the Study:

  • To estimate radiation doses to children from chest and head CT examinations.
  • To investigate the feasibility of establishing DRLs specifically for pediatric CT.
  • To provide recommendations for practical implementation and future re-evaluation of pediatric DRLs.

Main Methods:

  • Dose estimation for pediatric patients undergoing chest and head CT scans.
  • Analysis of patient dose data considering different CT scanners.
  • Grouping of data by age or weight, and potentially by indication, for DRL setting.

Main Results:

  • Patient dose data from diverse CT scanners should be stratified by age or weight groups for DRLs.
  • A continuous DRL curve as a function of patient weight is proposed for pediatric chest CT.
  • DRLs for pediatric head CT can be defined for specific age groups.

Conclusions:

  • Establishing pediatric DRLs for CT is feasible with appropriate data stratification.
  • Practical implementation requires awareness of calibration phantom details for pediatric protocols.
  • Regular re-evaluation (every 2-3 years) of pediatric DRL feasibility is recommended.

More Related Videos

Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform07:57

Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform

Published on: March 24, 2022

Related Concept Videos

Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Radiological Investigation I: X-ray and CT01:30

Radiological Investigation I: X-ray and CT

Radiological investigations, including X-rays and computed tomography (CT) scans, are critical for diagnosing and evaluating various medical conditions. These imaging techniques provide valuable insights into the body's internal structures, aiding in the detection of abnormalities, assessment of disease progression, and development of treatment strategies. This article delves into two primary radiological investigations, chest X-rays and CT scans, outlining their purpose, procedures, and the...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...